Back to Search Start Over

Early response to Tezepelumab in type-2 severe asthma patients non-responders to other biological treatments: a real-life study.

Authors :
Jiménez-Gómez M
Díaz-Campos RM
Gimeno-Díaz-De-Atauri Á
Fernández-Rodríguez C
Fernández-Crespo J
García-Moguel I
Source :
The Journal of asthma : official journal of the Association for the Care of Asthma [J Asthma] 2024 Oct; Vol. 61 (10), pp. 1347-1350. Date of Electronic Publication: 2024 May 09.
Publication Year :
2024

Abstract

Background: Biologic therapies play a crucial role in the treatment of severe asthma. Tezepelumab, a human monoclonal antibody (mAb), inhibits thymic stromal lymphopoietin, a pivotal factor in the pathophysiology of asthma. Although randomized clinical trials have demonstrated the efficacy of Tezepelumab, evidence gaps remain in real-world scenarios.<br />Objective: We sought investigate Tezepelumab's response in a clinical setting, focusing on patients who previously failed to other asthma mAbs.<br />Methods: Real-life study with severe uncontrolled asthma patients despite mAb treatment, requiring a switch to Tezepelumab. Follow-up was done four to six months after initiation of Tezepelumab. The primary endpoint was to evaluate the response in patients with poor response or intolerance to other mAbs.<br />Results: Nine patients were followed up during 7 months. Patients were predominantly middle-aged females with eosinophilic or eosinophilic-allergic phenotypes. Patients had a median failure rate of 2 mAbs (IQR 2-3), with an uncontrolled asthma (median of 2 severe exacerbations the previous year, airflow obstruction and 78% corticosteroid dependence). Tezepelumab demonstrated after 4 to 6 months of treatment reduce corticosteroid dependence (complete withdrawal in 2/7 patients), no exacerbations in 6/9, symptoms control improvement (Asthma Control Test score improved in 5/9) and modulate lung function (improving in 3/9 patients). These findings align with clinical trial results, suggesting Tezepelumab's potential in real-world settings.<br />Conclusion: In real-world scenarios, despite the study's limitations, our results underscore Tezepelumab's promise as a therapeutic option for uncontrolled severe asthma, and may be useful for non-responders to other mAbs. Further studies are needed to corroborate these findings.

Details

Language :
English
ISSN :
1532-4303
Volume :
61
Issue :
10
Database :
MEDLINE
Journal :
The Journal of asthma : official journal of the Association for the Care of Asthma
Publication Type :
Academic Journal
Accession number :
38686823
Full Text :
https://doi.org/10.1080/02770903.2024.2349605